期刊文献+

抗M型磷脂酶A2受体抗体在特发性膜性肾病治疗中的临床意义 被引量:7

Clinical significance of anti-M type phospholipase A2 receptor antibody in treatment of idiopathic membranous nephropathy
下载PDF
导出
摘要 目的探讨抗M型磷脂酶A2受体(PLA2R)抗体在特发性膜性肾病(IMN)治疗中的临床意义。方法纳入2013年4月至2014年6月间在南通大学附属医院住院并行肾活检的61例初治肾脏病患者,采用间接免疫荧光法检测血清抗PLA2R抗体的表达,并收集相关临床资料进行分析。结果 61例患者中,19例IMN患者血清抗PLA2R抗体阳性率为89.5%(17/19),42例非IMN患者血清抗PLA2R抗体阳性率为7.14%(3/42)。17例抗PLA2R抗体呈阳性的IMN患者的抗体滴度为1 000±680,高于抗PLA2R抗体阳性非IMN患者的抗体滴度(P<0.05);就诊时IMN患者抗PLA2R抗体滴度与病程、尿蛋白量、血清白蛋白、血肌酐或内生肌酐清除率以及胆固醇水平无相关性(P>0.05)。共14例IMN患者随访观察6个月,治疗早期抗PLA2R抗体降低幅度较尿蛋白更明显,同一时间点完全缓解者抗PLA2R抗体滴度阴性,治疗无效者抗体滴度最高;与高滴度组相比,低滴度组达到部分缓解的时间短[(1.16±0.41)个月vs(2.85±1.86)个月,P<0.05];相同用药方案治疗1个月后发现抗PLA2R抗体滴度与疗效呈负相关。结论间接免疫荧光法检测血清抗PLA2R抗体在IMN中具有较高的阳性率。抗PLA2R抗体低滴度患者较早达到缓解,抗体持续高滴度提示可能需要更换治疗方案。抗PLA2R抗体对IMN的临床诊断、鉴别诊断以及判断IMN病情活动、制定治疗方案具有重要的临床意义和指导价值。 Objective To investigate the clinical significance of anti-M type phospholipase A2 receptor( PLA2R) antibody in the treatment of idiopathic membranous nephropathy( IMN). Methods A total of 61 renal disease patients with renal biopsy from April2013 to June 2014 were enrolled. The anti-PLA2 R antibody in serum was detected by indirect immunofluorescence technique( IIFT).And the clinical,laboratory and pathological data were collected in this retrospective study. Results In the 19 IMN patients,the positive rate of anti-PLA2 R antibody was 89. 5%( 17 /19),while the positive rate of 42 non-IMN patients was 7. 14%( 3 /42). The average titer of anti PLA2 R antibody in 17 cases of first diagnosed IMN were 1 000 ± 680,which was significantly higher than those of nonIMN patients with positive PLA2 R antibody( P 〈0. 05). The PLA2 R antibody titer was independent during the IMN course and uncorrelated with the amount of urinary protein,serum albumin,serum creatinine,creatinine clearance rate and cholesterol levels. The PLA2 R antibody titer in the 14 patients who were first diagnosed IMN and followed up for 6 months reduced more obviously than the amount of urinary protein in the early stage of treatment. At the same time point,the PLA2 R antibody titers in the patients with complete remission were negative,and in the patients with ineffective remission the antibody titers were highest. Compared with patients with high PLA2 R antibody titer,the patients with low PLA2 R antibody titers underwent shorter remission time( 1. 16 ± 0. 41 months vs.2. 85 ± 1. 86 months,P〈 0. 05). The PLA2 R antibody titer was negatively correlated with the treatment efficacy in the patients after treatment with the same regimen for one month. Conclusion High positive rate of PLA2 R antibody detected by IIFT was found in IMN patients. The patients with low PLA2 R antibody titers may remit earlier. The sustained high titer of PLA2 R antibody indicates the therapeutic regimen should be changed. The detection of PLA2 R antibody presents important significance and clinical guiding value for clinical diagnosis,differential diagnosis,evaluation of disease activity and choice of treatment scheme.
出处 《临床检验杂志》 CAS CSCD 2015年第8期581-585,共5页 Chinese Journal of Clinical Laboratory Science
基金 国家自然科学基金青年科学基金(81200490) 江苏省卫生厅面上科研项目(201213) 南通市科技局社会发展项目(S11910)
关键词 M型磷脂酶A2受体 自身抗体 膜性肾病 特发性 M-type phospholipase A2 receptor autoantibody membranous nephropathy idiopathic
  • 相关文献

参考文献12

  • 1Hemnann SM, Sethi S, Fervenza FC. Membranous nephropathy: the start of a paradigm shift[J]. Curr Opin Nephrol Hypertens,2012, 21 (2) : 203-210.
  • 2Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranousglomerulonephritis due to anti-neutral endopeptidase antibodies [J]. N Engl J Med, 2002, 346(26) : 2053-2060.
  • 3Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1) : 11-21.
  • 4Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor au- toantibodies and clinical outcome in patients with primary membranous nephropathy[J]. J Am Soc Nephrol, 2014, 25(6) : 1357-1366.
  • 5Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 recep- tor antibody titer and subclass in idiopathic membranous nephropathy [J]. J Am Soc Nephml, 2012, 23(10) : 1735-1743.
  • 6Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy [J]. J Am Soc Nephrol, 2011, 22(6) : 1137-1143.
  • 7李世军,秦卫松,张明超,郑春霞,左科,陈惠萍,吴燕,刘志红.肿瘤相关膜性肾病:抗足细胞自身抗体与肾组织IgG亚型的检测[J].肾脏病与透析肾移植杂志,2011,20(1):12-17. 被引量:17
  • 8Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Throm- bospondin type-1 domain-containing 7A in idiopathic membranous ne- phropathy[J]. N Engl J Med, 2014, 371 (24) : 2277-2287.
  • 9Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a preva- lent population of patients with idiopathic membranous nephropathy [J]. Kidney Int, 2013, 83(5) : 940-948.
  • 10周广宇,金玲,于晶,张芝平.成人膜性肾病患者血清抗PLA2R抗体与病情的相关性[J].中华肾脏病杂志,2012,28(2):111-114. 被引量:63

二级参考文献25

  • 1Li LS,Liu ZH.Epidemiologic data of renal diseases from a single unit in China:analysis based on 13,519 renal biopsies.Kidney Int,2004,66(3):920-923.
  • 2Zeng CH,Chen HM,Wang RS,et al.Etiology and clinical characteristics of membranous nephropathy in Chinese patients.Am J Kidney Dis,2008,52(4):691-698.
  • 3Rihova Z,Honsova E,Merta M,et al.Secondary membranousnephropathy-one center experience.Ren Fail,2005,27(4):397-402.
  • 4Ronco PM.Paraneoplastic glomerulopathies:new insights into an old entity.Kidney Int,1999,56(1):355-377.
  • 5Brueggemeyer CD,Ramirez G.Membranous nephropathy:A concern for malignancy.Am J Kidney Dis,1987,9(1):23-26.
  • 6Beck LH Jr,Bonegio RG,Lambeau G,et al.M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.N Engl J Med,2009,361(1):11-21.
  • 7Keur I,Krediet RT,Arisz L.Glomerulopathy as a paraneoplastic phenomenon.Neth J Med,1989,34(5-6):270-284.
  • 8Burstein DM,Korbet SM,Schwartz MM.Membranous glomerulonephritis and malignancy.Am J Kidney Dis,1993,22(1):5-10.
  • 9Lefaucheur C,Stengel B,Nochy D,et al.Membranous nephropathy and cancer:Epidemiologic evidence and determinants of high-risk cancer association.Kidney Int,2006,70(8):1510-1517.
  • 10Li SJ,Zhang SH,Chen HP,et al.Mercury-induced membranousnephropathy:clinical and pathological features.Clin J Am Soc Nephrol,2010,5(3):439-444.

共引文献76

同被引文献77

  • 1Wasserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol, 1997,8 (4) : 664 - 674.
  • 2Glassock RJ. Diagnosis and natural course of membranous ne- phropathy. Seminars in Nephrology, 2003,23 (4) : 324 - 332.
  • 3Coenen M J, Hofstra JM, Debiec H, et al. Phospholipase A2 recep- tor(PLA2R) sequence variants in idiopathic membranous ne- phropathy. J Am Soc Nephrol,2013,24 ( 4 ) : 677 - 683.
  • 4Beck LH Jr, Bonegio RG, Lambeau G, et al. Mtype phospholipase A2 receptor as target antigen in idiopathic MN. N Engl J Med, 2009,361(1) :11 -21.
  • 5Hofstra JM, Beck LH Jr, Beck DM, et al. Anti - Phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol, 2011 ; 6 ( 6 ) : 1286 - 1291.
  • 6Qin W, Beck LJ,Zeng C, et al. Anti - phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol,2011, 22(6) :1137 - 1143.
  • 7Svobodova B, Honsova E, Ronco P, et al. Kidney biopsy is a sen- sitive tool for retrospective diagnosis of PLA2R - related mem- branous nephropathy. Nephrol Dial Transplant, 2013,28 ( 7 ) : 1839 - 1844.
  • 8Ronco P, Debiee H. Antigen identification in membranous ne- phropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrolb,2010,21 (4) :564-569.
  • 9Beck LH Jr,Salant DJ. Membranous nephropathy:recent travels and new roads ahead. Kidney Int,2010,77 (9) :765 -770.
  • 10Augert A, Payre C, de Launoit Y, et al. The M - type receptor PLA2R regulates senescence through the p53 pathway. EMBO - Rep, 2009,10 ( 3 ) : 271 - 277.

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部